Ann: ImpediMed Achieves Critical Mass in First Key Target State, page-17

agree with you on the Sharp announcement ....unless you are a short term trader and best of luck with making some bucks that way, most of us know this story unfolds next year ..... this qtr won't see much if any increase (setting low expectations), next qtr some uptick but not substantial and then the 4C in Jam 2024 is when you get your popcorn ready and then sit back and enjoy the show throughout 2024 .... that's the low hanging fruit ..... my concern is the work they do now over the next 12 months to get the tougher contracts in and expansion across the US ..... that will set up more showtime for 2025 if they execute well in the background over the next 12 months..... time will tell, although we need BOD members with experience on rapidly growing companies not just lifestyle and studies /capital raising .